Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05612789 · ClinicalTrials.gov registry record · NA
Improve Outcomes for Older Allogeneic Transplant Recipients
A NA study of Allogeneic Transplantation, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05612789: Recruiting NA study of Allogeneic Transplantation, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05612789 is a NA study of Allogeneic Transplantation that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05612789, a NA study of Allogeneic Transplantation, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.
Conditions Studied
Interventions
- BEHAVIORAL Exercise Program (Cohort A Prehab)
- BEHAVIORAL Exercise Program (Cohort B Rehab)
Study Locations (1)
Pennsylvania
- Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2031-06-01 |
| Phase | NA |
What NCT05612789 shows while recruiting
NCT05612789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Allogeneic Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Exercise Program (Cohort A Prehab) is the first listed.
NCT05612789 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05612789 about?
NCT05612789 is a clinical study titled "Improve Outcomes for Older Allogeneic Transplant Recipients". This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as...
What is the current status of trial NCT05612789?
This trial is currently recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2023-02-15. Estimated completion is 2031-06-01.
What conditions does trial NCT05612789 study?
This clinical trial studies the following conditions: Allogeneic Transplantation.
What interventions are being tested in trial NCT05612789?
The interventions under investigation include: Exercise Program (Cohort A Prehab) (BEHAVIORAL), Exercise Program (Cohort B Rehab) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05612789?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05612789 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05612789's enrollment target sits among peer trials
72 1090th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI